Dalbavancin U.S. approval delay
Partner's U.S. launch delayed due to additional data request; approval expected in February but uncertainty remains.
GLAND / Q3-FY26 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Cenexi quarterly volatility
Management acknowledged quarter-to-quarter fluctuations at Cenexi, which could impact near-term consolidated results.
GLP-1 capacity utilization risk
Despite expanding cartridge capacity, management is conservative on GLP-1 revenue, citing patent and pricing uncertainties.
CDMO contract ramp-up slower than expected
New CDMO contracts (e.g., oncology) start only by end-2028, with meaningful revenue contribution delayed.